Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus

被引:40
|
作者
Moore, Erica [1 ]
Huang, Michelle W. [1 ]
Putterman, Chaim [1 ,2 ,3 ]
机构
[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Div Rheumatol, F701N,1300 Morris Pk Ave, Bronx, NY 10461 USA
[3] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel
基金
美国国家卫生研究院;
关键词
angiotensin-converting enzyme inhibitors; biomarkers; microglial activation; neuroimaging; neuropsychiatric lupus; systemic lupus erythematosus; BLOOD-BRAIN-BARRIER; AUTOANTIBODY; DAMAGES;
D O I
10.1097/BOR.0000000000000682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Diagnosing and treating neuropsychiatric systemic lupus erythematosus (NPSLE) remains challenging as the pathogenesis is still being debated. In this review, we discuss studies evaluating recent advances in diagnostic methods, pathogenic mediators and potential treatments. Recent findings Screening tools used for neurodegenerative diseases were found to be both sensitive and moderately specific for cognitive dysfunction in NPSLE. Neuroimaging can be used to distinguish systemic lupus erythematosus (SLE) patients from healthy controls, but further refinement is needed to differentiate between lupus patients with and without neuropsychiatric manifestations. Elevated levels of specific molecules in the cerebrospinal fluid and/or serum, as well as the presence of certain autoantibodies, have been identified as potential biomarkers in attempts to facilitate a more accurate and objective diagnosis. Among such autoantibodies, anti-NR2 and anti-ribosomal P autoantibodies also have a pathogenic role, although newer studies demonstrate that blood-brain barrier damage may not always be required as previously believed. These and other observations, together with new evidence for disease attenuation after microglial modulation, suggest direct involvement of the central nervous system in NPSLE pathogenesis. Neuropsychiatric involvement of SLE includes a variety of symptoms that impact quality of life and patient prognosis. There have been recent advances in improving the diagnosis of NPSLE as well as in dissecting the underlying pathogenesis. The attenuation of neuropsychiatric disease in mouse models demonstrates the potential for targeted therapies, which are based on a clearer understanding of the pathogenesis of NPSLE. Further assessment of these treatments is required in NPSLE patients, as well as the potential use of neuroimaging to distinguish between SLE patients with or without neuropsychiatric manifestations.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 50 条
  • [21] Neuropsychiatric systemic lupus erythematosus
    M. Gina Navarrete
    Robin L. Brey
    [J]. Current Treatment Options in Neurology, 2000, 2 (5) : 473 - 485
  • [22] Pharmaceutical alternatives to the treatment of neuropsychiatric systemic lupus erythematosus
    Harten, P
    [J]. MEDIZINISCHE KLINIK, 2003, 98 (06) : 344 - 344
  • [23] Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus
    Ramos, PC
    Mendez, MJ
    Ames, PRJ
    Khamashta, MA
    Hughes, GRV
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (03) : 295 - 299
  • [24] The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors
    Stock, Ariel
    Wen, Jing
    Doerner, Jessica
    Putterman, Chaim
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S289 - S290
  • [25] An Insight on the Pathogenesis and Treatment of Systemic Lupus Erythematosus
    Ali, Murtaza
    Firoz, Chelapram K.
    Jabir, Nasimudeen R.
    Rehan, Mohd
    Khan, Mohd S.
    Tabrez, Shams
    [J]. ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (02) : 110 - 123
  • [26] Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE)
    Hermosillo-Romo, D
    Brey, RL
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (02): : 229 - 244
  • [27] Diagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update
    Unal, Dilara
    Cam, Veysel
    Emreol, Hulya Ercan
    Ozen, Seza
    [J]. PEDIATRIC DRUGS, 2024, 26 (04) : 381 - 395
  • [28] Immunological pathogenesis and treatment of systemic lupus erythematosus
    Pan, Lu
    Lu, Mei-Ping
    Wang, Jing-Hua
    Xu, Meng
    Yang, Si-Rui
    [J]. WORLD JOURNAL OF PEDIATRICS, 2020, 16 (01) : 19 - 30
  • [29] Pathogenesis and treatment of systemic lupus erythematosus nephritis
    Davidson, Anne
    Aranow, Cynthia
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (05) : 468 - 475
  • [30] Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management
    Oshrat E. Tayer-Shifman
    Kathleen S. Bingham
    Zahi Touma
    [J]. Drugs & Aging, 2022, 39 : 129 - 142